Home > Cardiology > HFA 2023 > HFA 2023 Highlights Podcast

HFA 2023 Highlights Podcast

Presented by
Robert van den Heuvel, Medicom
HFA 2023

In this episode, Medicom’s correspondent covers 6 presentations from the annual meeting of the Heart Failure Association (HFA 2023), held in Prague, Czech Republic from 20-23 May.
The topics discussed are:

  1. Aficamten may lower symptom burden in non-obstructive hypertrophic cardiomyopathy
    The open-label, dose-finding REDWOOD-HCM Cohort 4 study demonstrated that patients with non-obstructive hypertrophic cardiomyopathy achieve distinct symptom relief when treated with the myosin inhibitor aficamten. Moreover, angina symptom frequency was significantly reduced.
  2. ENACT-HF: Standardised diuretic protocol improves natriuresis in acute heart failure
    Following a natriuresis guided protocol in diuretic use led to a 64% increased natriuresis after 24 hours. In addition, duration of hospitalisation was 1 day shorter in the intervention group in the prospective ENACT-HF trial.
  3. NUDGE-FLU: Repeated electronic nudges improve flu vaccination rates in patients with HF
    Repeated electronic nudges and letters focusing on the cardiovascular benefits of flu vaccination are successful tools to motivate patients with heart failure (HF) to get vaccinated. The current pre-specified analysis of the NUDGE-FLU study also revealed alarmingly low vaccination rates in HF patients <65 years.
  4. Copper chelating agent improves biomarkers and quality of life in HF patients
    The TRACER-HF trial indicates that therapy with a copper chelator may have beneficial effects in heart failure patients and should be evaluated in further studies. In addition, the therapy did not affect blood pressure and heart rate.
  5. Haemodynamic monitoring improves quality of life and lowers hospitalisations in HF patients
    Remote pulmonary artery pressure monitoring met all primary and secondary endpoints in the MONITOR-HF trial. This was the first positive study of remote monitoring in European patients.
  6. AI-based technology successful in SARS-CoV-2 symptoms screening
    The language-based AI model Alexa performed similarly to a healthcare professional in SARS-CoV-2 symptoms screening in patients with heart failure (HF) and their caregivers in the VOICE-COVID-II trial. AI-based assistance could relieve healthcare systems, at least in simple tasks like symptom screening.

Enjoy listening!

Copyright ©2023 Medicom Medical Publishers

Posted on